Skip to main content

Table 1 Demographic, clinical and laboratory data of HD patients stratified by type of dyslipidaemia

From: ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients

Parameter

Dyslipidaemia

Without dyslipidaemia

P valuea

Atherogenic dyslipidaemia

Without atherogenic dyslipidaemia

 

by K/DOQI criteria

TG/HDL cholesterol ratio

P valuea

  

5.98 (3.81–30.83)

2.52 (0.47–3.79)

Demographic data

N = 459

N = 414

 

N = 454

N = 419

 

 Male gender, n, % of all

242 (52.7)

247 (59.7)

0.039*

263 (57.9)

226 (53.9)

0.235

 Age, years

66.8 (17.9–95.9)

67.1 (17.1–92.3)

0.944

66.3 (17.1–92.3)

68.3 (21.5–95.9)

0.162

Clinical data

 Main cause of ESRD

 Diabetic nephropathy, n, % of all

125 (27.2)

123 (29.7)

0.418

132 (29.1)

116 (27.7)

0.649

 Hypertensive nephropathy, n, % of all

95 (20.7)

83 (20.0)

0.878

97 (21.4)

81 (19.3)

0.509

 Chronic glomerulonephritis, n, % of all

66 (14.4)

68 (16.4)

0.457

65 (14.3)

69 (16.5)

0.431

 Chronic tubulointerstitial nephritis, n, % of all

41 (8.9)

41 (9.9)

0.708

45 (9.9)

37 (8.8)

0.666

 Coronary artery disease, n, % of all

160 (34.9)

160 (38.6)

0.246

188 (41.4)

132 (31.5)

0.002*

 RRT duration, years

5.5 (0.2–28.3)

5.9 (0.1–27.5)

0.143

5.8 (0.1–28.1)

5.6 (0.2–28.3)

0.444

 HD re-started after graft loss, n, % of all

25 (5.4)

22 (5.3)

0.970

25 (5.5)

22 (5.3)

0.778

 Life with graft, years

8.7 (0.0–21.0)

2.1 (0.0–17.0)

0.014*

8.3 (0.0–21.0)

3.0 (0.0–20.0)

0.082

 Dialysis duration, years

5.4 (0.2–28.3)

5.9 (0.1–27.3)

0.009*

5.7 (0.1–27.3)

5.6 (0.2–28.3)

0.613

 LF-HD, n, % of all

224 (48.8)

194 (46.9)

0.566

199 (43.8)

219 (52.3)

0.013*

 Chronic hepatitis B, n, % of all

5 (1.1)

8 (1.9)

0.555

6 (1.3)

7 (1.7)

0.884

 Chronic hepatitis C, n, % of all

31 (6.8)

22 (5.3)

0.455

29 (6.4)

24 (5.7)

0.790

 BMI, kg/m2

25.6 (12.8–59.2)

24.6 (14.3–63.5)

0.030*

26.4 (14.3–59.2)

24.2 (12.8–63.5)

< 0.000001*

 BMI > 30 kg/m2 (obesity), n, % of all

91 (22.8)

51 (15.5)

0.016*

102 (26.1)

40 (11.8)

< 0.00001*

Laboratory data

 HDL cholesterol, mg/dL

40 (16–103)

39.1 (6–103)

0.719

33 (6–82)

47 (19–103)

< 0.000001*

 Triglycerides, mg/dL

172.5 (40.6–856)

121 (29.8–585)

< 0.00001*

201 (46–856)

109 (29.8–260)

< 0.000001*

 LDL cholesterol, mg/dL

120.1 (41.8–512)

73.4 (13.3–99.5)

< 0.00001*

102.4 (17–512)

93 (13.3–255)

0.0004*

 Non-HDL cholesterol, mg/dL

158.7 (53.6–593)

99 (27–157)

< 0.00001*

148 (44–593)

116.7 (27–282)

< 0.000001*

 Adropin, ng/mLb

2.02 (0.22–8.01)

2.15 (0.76–8.46)

0.491

1.85 (0.22–6.98)

2.46 (0.87–8.46)

0.002*

 ALT, IU/L

14 (0.6–195)

13 (2–131)

0.243

13 (2–195)

14 (0.6–135)

0.922

 PTH, pg/mL

407.7 (7.3–3757)

355.3 (13.7–2991.5)

0.082

413 (19.5–3118.3)

361.4 (7.3–3757)

0.063

  1. aThe Mann-Whitney U test was used to compare continuous variables. Chi-squared test with Yates correction was applied to compare dichotomous variables
  2. bDetermined in 126 patients: 67 with dyslipidaemia and 59 without dyslipidaemia by K/DOQI criteria; 73 with atherogenic dyslipidaemia and 53 without atherogenic dyslipidaemia
  3. Abbreviations: ALT alanine aminotransferase, BMI body mass index, ESRD end-stage renal disease, LF-HD low flux haemodialysis, HD haemodialysis, PTH parathyroid hormone, RRT renal replacement therapy, TC total cholesterol, TG triglycerides
  4. P-values below 0.05 are indicated by an asterisk
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us